Bristol-Myers Squibb Company (BMY)vsConstellation Energy Corp (CEG)
BMY
Bristol-Myers Squibb Company
$58.94
+2.70%
HEALTHCARE · Cap: $120.03B
CEG
Constellation Energy Corp
$303.32
+2.87%
UTILITIES · Cap: $106.82B
Smart Verdict
WallStSmart Research — data-driven comparison
Bristol-Myers Squibb Company generates 89% more annual revenue ($48.19B vs $25.53B). BMY leads profitability with a 14.6% profit margin vs 9.1%. BMY appears more attractively valued with a PEG of 2.26. BMY earns a higher WallStSmart Score of 64/100 (C+).
BMY
Buy64
out of 100
Grade: C+
CEG
Hold43
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+63.0%
Fair Value
$161.93
Current Price
$58.94
$102.99 discount
Margin of Safety
-441.4%
Fair Value
$51.14
Current Price
$303.32
$252.18 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 40 in profit
Large-cap with strong market position
Attractively priced relative to earnings
Strong operational efficiency at 28.2%
Generating 1.6B in free cash flow
Large-cap with strong market position
Areas to Watch
Expensive relative to growth rate
1.3% revenue growth
Distress zone — elevated risk
Elevated debt levels
Premium valuation, high expectations priced in
Expensive relative to growth rate
Earnings declined 48.9%
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : BMY
The strongest argument for BMY centers on Return on Equity, Market Cap, P/E Ratio.
Bull Case : CEG
The strongest argument for CEG centers on Market Cap. Revenue growth of 12.9% demonstrates continued momentum.
Bear Case : BMY
The primary concerns for BMY are PEG Ratio, Revenue Growth, Altman Z-Score. Debt-to-equity of 2.55 is elevated, increasing financial risk.
Bear Case : CEG
The primary concerns for CEG are P/E Ratio, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
CEG carries more volatility with a beta of 1.11 — expect wider price swings.
CEG is growing revenue faster at 12.9% — sustainability is the question.
BMY generates stronger free cash flow (1.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
BMY scores higher overall (64/100 vs 43/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Bristol-Myers Squibb Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Bristol Myers Squibb (BMS) is an American multinational pharmaceutical company, headquartered in New York City. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
Visit Website →Constellation Energy Corp
UTILITIES · UTILITIES - INDEPENDENT POWER PRODUCERS · USA
Constellation Energy Corporation is an energy producer in the United States. The company is headquartered in Baltimore, Maryland.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?